Romiplostim N01 plus rituximab for ITP that didn't respond to oral TPO-RA
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new combination of two medicines—romiplostim N01 (a shot to raise platelets) and rituximab (an infusion that calms the immune system)—for people with primary immune thrombocytopenia (ITP) who have not had enough improvement from oral TPO-RA pills like hetrombopag or eltrombopag. It aims to see if this combination works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary immune thrombocytopenia (ITP), meaning it is not caused by another condition.
- You are 14 years or older.
- You have tried at least one ITP treatment before, including an oral TPO-RA pill (like hetrombopag or eltrombopag) for at least 4 weeks, and it did not work well enough.
- Your platelet count is very low (less than 30) or is less than 50 with active bleeding that is serious.
- You are not taking high doses of steroids (no more than 4 tablets of prednisone or methylprednisolone per day) and your dose has been stable for at least 2 weeks.
- You have not had IVIG (intravenous immunoglobulin) in the last 2 weeks, nor a platelet transfusion in the last week.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests romiplostim, a weekly injection, for patients with ITP (a blood disorder where the body destroys its own platelets) who did not respond to or could not tolerate oral medications. It aims to help raise platelet counts and reduce bleeding risk.
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
This trial tests if adding romiplostim (a drug that helps make platelets) to standard steroid treatment works better than steroids alone for adults who have not been treated for ITP before. It is for people with low platelet counts and may help reduce bleeding.
This trial tests whether a weekly injection of romiplostim can safely raise platelet counts in children with chronic immune thrombocytopenia (ITP) that has not improved with standard treatments. If effective, it may reduce bleeding risk and help children avoid more severe complications.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
Hear when a new Primacy Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.